Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study)
Diego Orsini,Giacomo Caldarola,Annunziata Dattola,Elena Campione,Nicoletta Bernardini,Pasquale Frascione,Clara De Simone,Antonio G. Richetta,Marco Galluzzo,Nevena Skroza,Chiara Assorgi,Emanuele Amore,Gennaro M. Falco,Ruslana Gaeta Shumak,Fabio Artosi,Giulia Maretti,Concetta Potenza,Luca Bianchi,Giovanni Pellacani,Ketty Peris,Claudio Bonifati,Dario Graceffa,Diego OrsiniGiacomo CaldarolaAnnunziata DattolaElena CampioneNicoletta BernardiniPasquale FrascioneClara De SimoneAntonio G. RichettaMarco GalluzzoNevena SkrozaChiara AssorgiEmanuele AmoreGennaro M. FalcoRuslana Gaeta ShumakFabio ArtosiGiulia MarettiConcetta PotenzaLuca BianchiGiovanni PellacaniKetty PerisClaudio BonifatiDario Graceffaa Clinical Dermatology Unit,IFO-San Gallicano Dermatological Institute-IRCCS,Rome,Italyb UOC di Dermatologia,Dipartimento di Scienze Mediche e Chirurgiche,Fondazione Policlinico Universitario A. Gemelli - IRCCS,Rome,Italyc Dermatologia,Dipartimento di Medicina e Chirurgia Traslazionale,Università Cattolica del Sacro Cuore,Rome,Italyd Unit of Dermatology,Department of Internal Medicine and Medical Specialties,Sapienza University,Rome,Italye Dermatology Unit,Department of Systems Medicine,University of Rome Tor Vergata,Rome,Italyf Dermatology Unit "Daniele Innocenzi" ASL LATINA,Department of Medical-Surgical Sciences and Biotechnologies,Sapienza University of Rome,Polo Pontino,Italyg Oncologic and Preventive Dermatology Unit,IFO-San Gallicano Dermatological Institute-IRCCS,Rome,Italyh Section of Dermatology,Department of Clinical Medicine and Surgery,University of Naples Federico II Napoli Italyi Department of Neurosciences,Mental Health and Sensory Organs,"Sapienza" University of Rome,Rome,Italy
DOI: https://doi.org/10.1080/09546634.2024.2319304
2024-02-29
Journal of Dermatological Treatment
Abstract:Purpose of the article: Interleukin-23 inhibitors, such as tildrakizumab, have emerged as safe and effective options for the management of psoriasis. Yet their efficacy in elderly patients (aged 65 years or more), particularly in those with difficult-to-treat areas involvement, remains insufficiently explored. We conducted this real-life retrospective multicentric observational study to assess the effectiveness of tildrakizumab in elderly patients with moderate-to-severe psoriasis, with involvement of difficult-to-treat areas. Materials and methods: We enrolled forty-nine patients aged 65 years old or more (mean age 73.1 ± 6.0), all treated with tildrakizumab for at least 28 weeks. The effectiveness of tildrakizumab was assessed by Static Physician's Global Assessment of Genitalia (sPGA-G), fingernail-PGA (f-PGA), palmoplantar PGA (pp-PGA), scalp-specific PGA (sc-PGA), and Psoriasis Area and Severity Index (PASI) scores. Results: Significant improvements in PASI scores were observed within 28 weeks of treatment, with 77.5%, 60%, and 45.2% of patients achieving PASI75, PASI90, and PASI100, respectively. The mean PASI decreased significantly from baseline (13.6 ± 9.9) to 1.3 ± 1.7 at week 28. More than 90% of patients had clear sPGA-G and pp-PGA scores and over 70% had clear f-PGA and sc-PGA scores after 28 weeks. Conclusions: Our findings suggest that tildrakizumab could be a valuable option for the treatment of elderly patients, including those with difficult-to-treat areas involvement.
dermatology